» Articles » PMID: 15147424

Cancer After Kidney Transplantation in the United States

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2004 May 19
PMID 15147424
Citations 276
Authors
Affiliations
Soon will be listed here.
Abstract

Previous reports of cancer after kidney transplantation have been limited by small numbers of patients in single-center studies and incomplete ascertainment of cases in large registries. We examined rates of malignancies among first-time recipients of deceased or living donor kidney transplantations in 1995-2001 (n = 35 765) using Medicare billing claims. For most common tumors, e.g. colon, lung, prostate, stomach, esophagus, pancreas, ovary and breast, cancer rates were roughly twofold higher after kidney transplantation compared with the general population. Melanoma, leukemia, hepatobiliary tumors, cervical and vulvovaginal tumors were each approximately fivefold more common. Testicular and bladder cancers were increased approximately threefold, while kidney cancer was approximately 15-fold more common. Kaposi's sarcoma, non-Hodgkin's lymphomas, and nonmelanoma skin cancers were more than 20-fold increased than in the general population. Compared with patients on the waiting list, several tumors were more common after transplantation (p < 0.01): nonmelanoma skin cancers (2.6-fold), melanoma (2.2-fold), Kaposi's sarcoma (9.0-fold), non-Hodgkin's lymphoma (3.3-fold), cancer of the mouth (2.2-fold), and cancer of the kidney (39% higher). The rates for most malignancies are higher after kidney transplantation compared with the general population. Cancer should continue to be a major focus of prevention in kidney transplantation.

Citing Articles

Multicenter, Real-World Clinical Evaluation of Alemtuzumab and Anti-Thymocyte Globulin for Severe Acute T Cell-Mediated Kidney Transplant Rejection.

van Vugt L, Tegzess E, van der Zwan M, Clahsen-van Groningen M, de Winter B, Vart P Clin Transplant. 2024; 38(12):e70046.

PMID: 39636744 PMC: 11620281. DOI: 10.1111/ctr.70046.


Challenges and advances in the management of post-transplant lymphoproliferative disease.

Sandes-Freitas T, Domingues-da-Silva R, Duarte F J Bras Nefrol. 2024; 46(4):e2024E012.

PMID: 39586013 PMC: 11588344. DOI: 10.1590/2175-8239-JBN-2024-E012en.


Cancer Screening and Cancer Treatment in Kidney Transplant Recipients.

Vieira M, Arai H, Nicolau C, Murakami N Kidney360. 2024; 5(10):1569-1583.

PMID: 39480669 PMC: 11556922. DOI: 10.34067/KID.0000000000000545.


Surveillance strategies for renal cell carcinoma in the renal allograft: balancing early detection and resource utilization.

Rajagopal A Proc (Bayl Univ Med Cent). 2024; 37(5):839-840.

PMID: 39165816 PMC: 11332631. DOI: 10.1080/08998280.2024.2384343.


Elucidating the nexus between onco-immunology and kidney transplantation: An insight from precision medicine perspective.

Purnomo A, Nurkolis F, Syahputra R, Moon S, Lee D, Taslim N Heliyon. 2024; 10(13):e33751.

PMID: 39040404 PMC: 11261886. DOI: 10.1016/j.heliyon.2024.e33751.